Pacer Advisors Inc. Purchases Shares of 416,191 Emergent Biosolutions Inc. $EBS

Pacer Advisors Inc. purchased a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS) in the first quarter, according to its most recent filing with the SEC. The firm purchased 416,191 shares of the biopharmaceutical company’s stock, valued at approximately $3,454,000. Pacer Advisors Inc. owned 0.81% of Emergent Biosolutions at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EBS. Bank of America Corp DE boosted its position in shares of Emergent Biosolutions by 24.8% during the 1st quarter. Bank of America Corp DE now owns 183,443 shares of the biopharmaceutical company’s stock valued at $1,523,000 after purchasing an additional 36,499 shares in the last quarter. Quantinno Capital Management LP bought a new stake in Emergent Biosolutions in the first quarter worth approximately $127,000. Renaissance Technologies LLC lifted its stake in Emergent Biosolutions by 13.7% in the first quarter. Renaissance Technologies LLC now owns 656,047 shares of the biopharmaceutical company’s stock valued at $5,445,000 after buying an additional 78,900 shares during the period. Sei Investments Co. bought a new position in shares of Emergent Biosolutions during the 1st quarter worth approximately $159,000. Finally, State of Wyoming bought a new position in shares of Emergent Biosolutions during the 1st quarter worth approximately $166,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent Biosolutions Trading Down 29.6%

Shares of Emergent Biosolutions stock opened at $5.31 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.08 and a current ratio of 4.29. Emergent Biosolutions Inc. has a 52 week low of $5.06 and a 52 week high of $14.06. The stock has a 50 day moving average price of $7.90 and a two-hundred day moving average price of $8.79. The stock has a market capitalization of $273.97 million, a PE ratio of -1.50 and a beta of 2.35.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 14.83% and a negative net margin of 22.95%.The company had revenue of $234.30 million for the quarter, compared to analyst estimates of $177.50 million.

Insider Buying and Selling

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the transaction, the senior vice president owned 159,098 shares in the company, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EBS. UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Finally, Weiss Ratings lowered shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Emergent Biosolutions presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Key Headlines Impacting Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Second-quarter results exceeded expectations: Emergent reported adjusted EPS of $0.60, compared with the consensus estimate of a $0.08 loss, while revenue reached $234.3 million versus expectations of $177.5 million. Emergent Biosolutions: Q2 Earnings Snapshot
• Positive Sentiment: Biodefense demand remains a potential long-term catalyst: The company highlighted increased government and public-health attention to biological threats, including geopolitical conflict, synthetic biology and the possible misuse of biological agents. Cross-Sector Collaboration Against Biological Threats
• Neutral Sentiment: Management is undertaking a restructuring: The plan is part of broader turnaround efforts and includes layoffs, signaling an attempt to reduce costs and improve operating performance, but it may also create near-term disruption and expenses. Emergent BioSolutions Announces Restructuring
• Negative Sentiment: Full-year revenue guidance was cut well below analyst expectations: Emergent now expects 2026 revenue of $645 million to $675 million, compared with the consensus estimate of approximately $730.4 million. Emergent BioSolutions Shares Plunge After 2026 Guidance Cut
• Negative Sentiment: Third-quarter guidance was also materially below expectations: Revenue is projected at $110 million to $130 million, versus analyst expectations of about $209 million. The weak forward outlook and workforce reductions are driving the negative investor reaction despite the quarterly beat. Emergent Bio Slips Despite Q2 Beat After Guidance Cut

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.